<(Z)-3-nonenyl>triphenyl phosphonium tosylate | 82393-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: <(Z)-3-nonenyl>triphenyl phosphonium tosylate
• 英文别名: 3-nonenyltriphenylphosphonium tosylate；3-cis-nonen1-yl-triphenylphosphonium toluenesulphonate；3-(Z)-nonenyl-triphenylphosphonium tosylate；3(Z)-nonenyltriphenylphosphonium tosylate；4-methylbenzenesulfonate;[(Z)-non-3-enyl]-triphenylphosphanium
• CAS: 82393-41-7
• 化学式: C₇H₇O₃S*C₂₇H₃₂P
• 分子量: 558.722
• InChiKey: WGBNNSJFWXZTMC-NAFXZHHSSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  7.41
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  <(Z)-3-nonenyl>triphenyl phosphonium tosylate 在 正丁基锂 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 为溶剂， 生成 Phosphorane of (Z)-3-nonen-1-yl-triphenylphosponium bromide
  参考文献：
  名称：

  Synthesis of the 7-cis isomer of the natural leukotriene d4

  摘要：

  DOI：

  10.1016/s0040-4039(00)86776-3
• 作为产物：
  描述：

  1-0-p-Toluenesulphonyl-3(Z)-nonene 以 乙腈 为溶剂， 以66%的产率得到<(Z)-3-nonenyl>triphenyl phosphonium tosylate
  参考文献：
  名称：

  Leukotriene antagonists

  摘要：

  白三烯拮抗剂包括具有以下示例公式表示的化合物，其包括酯、酰胺和其生理学上可接受的盐。这些化合物保留了天然的5(S) 6(R)构型，5-羟基团和天然的不饱和尾部，肽被一种替代的芳香核取代，通过硫或氧取代物连接一个取代物到6位。

  公开号：

  EP0410244A1

文献信息

• Acidic Opening of the Dihydropyran Ring of Hexa-<i>O</i>-acetyl-D-lactal and Subsequent Chain Elongation. Novel Approach to the Synthesis of Low Molecular Weight<i>O</i>-Glycosides Containing a Diacetoxypolyene Aglycone Moiety
  作者：G. A. Tolstikov、A. G. Tolstikov、O. F. Prokopenko、L. M. Khalilov、V. N. Odinokov

  DOI：10.1055/s-1990-26932

  日期：——

  Low molecular weight O-glycosides containing a diacetoxypolyene aglycone moiety were prepared by chain elongation with phosphoranes or with a phosphonate of (2E,4S,5R)-5,6-diacetoxy-4-(2,3,4,6-tetra-O-acetyl-ß-D-galactopyranyloxy) -2-hexenal (2), which was prepared from hexa-O-acetyl-D-lactal by acidic ring opening and subsequent acetylation.

  含有二乙酸聚烯糖苷片段的低分子量O-糖苷，是通过磷烷或（2E,4S,5R）-5,6-二乙酰氧基-4-（2,3,4,6-四-O-乙酰基-β-D-半乳糖吡喃糖氧基）-2-己烯醛（2）的磷酸酯进行链延长制备的，而（2）是从六-O-乙酰基-D-乳糖通过酸性环开裂和后续乙酰化反应制备的。
• Synthesis of leukotriene A4 methyl ester from D-glucose
  作者：S.Richard Baker、Derek W. Clissold、Alexander McKillop

  DOI：10.1016/0040-4039(88)85316-4

  日期：1988.1

  A high yielding synthesis of leukotriene A4 methyl ester is described which uses D-glucose as starting material

  描述了以D-葡萄糖为原料的白三烯A 4甲酯的高产率合成
• Novel intermediates for the production of pharmaceuticals
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0201823A2

  公开（公告）日：1986-11-20

  There are disclosed compounds of the formula in which R1 is an alkenyl or alkynyl group optionally substituted with an optionally substituted phenyl group and containing from 5 to 30 carbon atoms, and R3, R4 and R5 are each selected from hydrogen, carboxyl, C2.5 alkoxycarbonyl, C1-4 alkyl, C1-4 alkoxy, hydroxyl, optionally protected tetrazolyl, halo, trifluoromethyl, nitrile, nitro and -CONR210 where each R10 is hydrogen or C1-4 alkyl. The compounds are intermediates useful for preparing pharmaceutical compounds of the formula in which R1, R3, R4 and R5 have the values given above and R2 is optionally substituted phenyl or optionally substituted C1-10 alkyl.

  公开了如下式的化合物 其中 R1 是任选被任选取代的苯基取代且含有 5 至 30 个碳原子的烯基或炔基，R3、R4 和 R5 分别选自氢、羧基、C2.5 烷氧基羰基、C1-4 烷基、C1-4 烷氧基、羟基、任选保护的四唑基、卤代、三氟甲基、腈、硝基和-CONR210，其中每个 R10 是氢或 C1-4 烷基。 这些化合物是用于制备以下式子的药物化合物的中间体 其中 R1、R3、R4 和 R5 具有上述值，R2 是任选取代的苯基或任选取代的 C1-10 烷基。
• Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes
  作者：Rudolf Hanko、Michael D. Hammond、Romanis Fruchtmann、Joerg Pfitzner、Graham A. Place

  DOI：10.1021/jm00166a013

  日期：1990.4

  The synthesis of novel 1-thio-substituted butadienes, designed as mechanism-based 5-lipoxygenase inhibitors, is described. The structure of these compounds closely resembles a proposed high-energy intermediate during the lipoxygenation of arachidonic acid. They demonstrate 5-lipoxygenase inhibition in vitro and in vivo. The most potent compound is 15a with an IC50 of 1.8 microM in vitro. LTC4 release was inhibited by 80% after intraperitoneal administration of 15c at a dose of 2 mg/kg.
• Araliphatic sulphides,sulphones and sulphoxides and their pharmaceutical use
  申请人：Lilly Industries Limited

  公开号：EP0134111B1

  公开（公告）日：1988-12-07